Trial Profile
A Phase I Trial of Olaparib in Addition to Cisplatin-based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NHSCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Olaparib (Primary) ; Ropidoxuridine (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms ORCA-2
- 12 Dec 2023 Planned End Date changed from 1 Sep 2023 to 1 Apr 2024.
- 09 May 2023 Planned End Date changed from 1 Mar 2023 to 1 Sep 2023.
- 01 Nov 2022 Planned End Date changed from 1 Jun 2022 to 1 Mar 2023.